Genix Pharmaceuticals Corporation
GENPF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | $0 | $0 | -$1 |
| % Margin | – | – | – | -1,476.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $19 | $30 | $27 | $60 |
| SG&A Expenses | $32 | $30 | $27 | $60 |
| Sales & Mktg Exp. | $13 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | $25 | $37 |
| Operating Expenses | $32 | $28 | $52 | $97 |
| Operating Income | -$32 | -$28 | -$52 | -$98 |
| % Margin | – | – | – | -144,030.9% |
| Other Income/Exp. Net | -$51 | -$24 | -$55 | $252 |
| Pre-Tax Income | -$84 | -$52 | -$107 | $154 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$60 | -$52 | -$107 | $154 |
| % Margin | – | – | – | 226,436.8% |
| EPS | -0.001 | -0.001 | -0.002 | 0.003 |
| % Growth | -11.1% | 50% | -169.2% | – |
| EPS Diluted | -0.001 | -0.001 | -0.002 | 0.003 |
| Weighted Avg Shares Out | 59,263 | 59,224 | 59,224 | 59,244 |
| Weighted Avg Shares Out Dil | 59,224 | 59,224 | 59,224 | 59,224 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $31 | $43 | $40 | $35 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$32 | -$9 | -$67 | $190 |
| % Margin | – | – | – | 279,050% |